Dec 26, 2024
Markwayne Mullin- Amount
- $50,001 to $100,000
- Filed
- Jan 3, 2025
Congress ticker disclosure profile
As of August 1 at 7:35 AM EDT
Public STOCK Act rows mentioning
A factual page for public Congressional disclosures that reference IEMG. Veridion shows filed rows, disclosed amount ranges, dates, and source links. It does not imply motive or wrongdoing.
90d rows
0
Feed lifetime
26
Member filers
4
Disclosed ranges
$83K
Most active member desks
20 buys vs 6 sells
Latest trade Dec 26, 2024
Dec 26, 2024
Markwayne MullinNov 27, 2024
Markwayne MullinMay 23, 2019
Alan S. LowenthalDec 24, 2018
Thomas MacarthurDec 3, 2018
Alan S. LowenthalSep 18, 2018
Thomas MacarthurJun 25, 2018
Thomas MacarthurJan 12, 2018
Thomas MacarthurDec 26, 2017
Thomas MacarthurAug 17, 2017
Thomas MacarthurJun 26, 2017
Thomas MacarthurMay 16, 2017
Thomas MacarthurJan 9, 2017
Thomas MacarthurDec 28, 2016
Thomas MacarthurJul 25, 2016
Thomas MacarthurJun 28, 2016
Thomas MacarthurFeb 19, 2016
Thomas MacarthurDec 28, 2015
Thomas MacarthurDec 16, 2015
Thomas MacarthurJul 1, 2015
Thomas MacarthurJun 1, 2015
Thomas MacarthurMar 18, 2015
Thomas MacarthurMar 3, 2015
Thomas MacarthurFeb 23, 2015
Thomas MacarthurJan 30, 2015
Thomas MacarthurSep 25, 2014
Ed Whitfield| Date | Member | Action | Amount | Filed | Receipt |
|---|---|---|---|---|---|
| Dec 26, 2024 | Markwayne Mullin | Buy | $50,001 to $100,000 | Jan 3, 2025 | Open card |
| Nov 27, 2024 | Markwayne Mullin | Buy | $1,001 to $15,000 | Dec 19, 2024 | Open card |
| May 23, 2019 | Alan S. Lowenthal | Sell | Receipt pending ingestion | May 31, 2019 | Receipt pending ingestion |
| Dec 24, 2018 | Thomas Macarthur | Buy | Receipt pending ingestion | Jan 11, 2019 | Open card |
| Dec 3, 2018 | Alan S. Lowenthal | Buy | Receipt pending ingestion | Dec 9, 2018 | Receipt pending ingestion |
| Sep 18, 2018 | Thomas Macarthur | Sell | Receipt pending ingestion | Oct 6, 2018 | Open card |
| Jun 25, 2018 | Thomas Macarthur | Buy | Receipt pending ingestion | Jul 10, 2018 | Open card |
| Jan 12, 2018 | Thomas Macarthur | Buy | Receipt pending ingestion | Feb 5, 2018 | Open card |
| Dec 26, 2017 | Thomas Macarthur | Buy | Receipt pending ingestion | Jan 10, 2018 | Open card |
| Aug 17, 2017 | Thomas Macarthur | Buy | Receipt pending ingestion | Sep 7, 2017 | Open card |
| Jun 26, 2017 | Thomas Macarthur | Buy | Receipt pending ingestion | Jul 9, 2017 | Open card |
| May 16, 2017 | Thomas Macarthur | Sell | Receipt pending ingestion | Jun 17, 2017 | Open card |
| Jan 9, 2017 | Thomas Macarthur | Buy | Receipt pending ingestion | Feb 8, 2017 | Open card |
| Dec 28, 2016 | Thomas Macarthur | Buy | Receipt pending ingestion | Jan 7, 2017 | Open card |
| Jul 25, 2016 | Thomas Macarthur | Sell | Receipt pending ingestion | Aug 6, 2016 | Open card |
| Jun 28, 2016 | Thomas Macarthur | Buy | Receipt pending ingestion | Jul 8, 2016 | Open card |
| Feb 19, 2016 | Thomas Macarthur | Buy | Receipt pending ingestion | Mar 3, 2016 | Open card |
| Dec 28, 2015 | Thomas Macarthur | Buy | Receipt pending ingestion | Jan 6, 2016 | Open card |
| Dec 16, 2015 | Thomas Macarthur | Sell | Receipt pending ingestion | Jan 6, 2016 | Open card |
| Jul 1, 2015 | Thomas Macarthur | Buy | Receipt pending ingestion | Aug 6, 2015 | Open card |
| Jun 1, 2015 | Thomas Macarthur | Buy | Receipt pending ingestion | Jul 11, 2015 | Open card |
| Mar 18, 2015 | Thomas Macarthur | Sell | Receipt pending ingestion | Apr 11, 2015 | Open card |
| Mar 3, 2015 | Thomas Macarthur | Buy | Receipt pending ingestion | Apr 11, 2015 | Open card |
| Feb 23, 2015 | Thomas Macarthur | Buy | Receipt pending ingestion | Mar 11, 2015 | Open card |
| Jan 30, 2015 | Thomas Macarthur | Buy | Receipt pending ingestion | Mar 5, 2015 | Open card |
| Sep 25, 2014 | Ed Whitfield | Buy | Receipt pending ingestion | Oct 8, 2014 | Open card |
Source creed
This page is assembled from public STOCK Act disclosure records in the Veridion warehouse. 2 of 26 filed rows include disclosed amount ranges (7.7%). Rows without ranges stay labeled. Identification only; it does not imply motive or wrongdoing.
Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.